Manufacturer
Eisai Co., Ltd.
Contents
Lenvatinib
Indication
Progressive, locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid carcinoma (DTC). In combination w/ everolimus for advanced renal cell carcinoma (RCC) following 1 prior vascular endothelial growth factor-targeted therapy.
Instruction
May be taken with or without food: Take at the same time each day. Swallow whole w/ water. May add cap to a spoonful of water or apple juice in a small glass to produce a susp. Cap must be left in the liqd for at least 10 min & stirred for at least 3 min to dissolve cap shells. Rinse glass w/ the same amount of water or apple juice & drink.
Drug interaction
Decreased exposure to oral CYP3A4/P-gp substrates eg, astemizole, terfenadine, cisapride, pimozide, quinidine, bepridil or ergot alkaloids (ergotamine, dihydroergotamine). Reduced hormonal contraceptive effectiveness.
Malaysia
